News | Breast Imaging | April 04, 2023

A first-of-its-kind removable wire-free marker and new generation localization system will improve efficiency for physicians and the lives of the breast cancer patients they care for 

A First-of-its-Kind Removable Wire-free Marker and New Generation Localization System will Improve Efficiency for Physicians and the Lives of the Breast Cancer Patients they Care for

April 4, 2023 — MOLLI Surgical, the company that is pushing the boundaries of precision surgery, today announced the launch of two new products, MOLLI 2 and MOLLI re.markable. The latest products, including the industry's first tool that ensures lesions are accurately marked, are paving the way for the next generation of healthcare. They deliver on the company's commitment to elevate the patient experience, refine precision surgery, and boost physicians’ confidence. 

MOLLI 2 is an evolution in MOLLI Surgical’s award-winning platform technology that allows surgeons to pinpoint cancerous tissue for faster, more accurate, and potentially improved cosmesis while significantly improving the patient experience. The wire-free technology includes the MOLLI Marker — about the size of a sesame seed — that can be detected using MOLLI 2. The MOLLI Marker is the smallest on the market and precisely marks where lesions are located before breast cancer surgery. The MOLLI Tablet then displays the distance — and now direction — between the tip of MOLLI 2 and the MOLLI Marker in millimeters. MOLLI 2 is easy to use, reliable, and precise, delivering improved efficiency and improving patient outcomes. MOLLI re.markable is a revolutionary new tool helping physicians accurately mark lesions by allowing radiologists and surgeons to reposition a localization marker with minimal impact or discomfort for patients. If the original placement was suboptimal, the localization marker can be removed without requiring invasive surgery or a large biopsy needle. 

“As a surgeon, my ultimate goal is always to help as many patients as possible while delivering the highest quality of care. These two products, used separately or together, will be a game changer for me in the operating room,” said Dr. Rakhshanda L. Rahman, Medical Director of the Breast Center of Excellence at the UMC Cancer Center. “MOLLI 2 will make it easier than ever to deliver exceptional outcomes and experiences for my patients.” 

“At MOLLI Surgical, we're constantly refining, innovating, and driving the future of healthcare by addressing the real clinical problems facing healthcare teams. The release of these two new products demonstrates our continued rapid pace of evolution in our technology,” said Ananth Ravi, President and CEO of MOLLI Surgical. “Our approach to innovation has always kept patient experience at the forefront. The launch of MOLLI 2 and MOLLI re.markable will improve the patient experience by creating the simplest possible process for accurate breast surgery.” 

MOLLI Surgical’s new products are now available to surgeons and radiologists. Click here to learn more.  

For more information: www.mollisurgical.com 


Related Content

News | HIMSS

March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...

Time March 06, 2026
arrow
News | Women's Health

March 4, 2026 — QT Imaging Holdings recently announced that Mary W. Yamashita, MD will serve as medical advisor to the ...

Time March 06, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Women's Health

March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...

Time March 03, 2026
arrow
News | FDA

Feb. 26, 2026 — AS Software, a provider of specialty-focused ultrasound reporting solutions, has announced that the U.S ...

Time March 02, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
Subscribe Now